Element held its inaugural virtual event, Beyond, diving deep into the science behind our newest technologies—our Trinity™ targeted sequencing workflow and the AVITI24™ next-gen multiomics platform. To kick off the event, our own DJ Freestyle entertained attendees and kept the energy high (check out his playlist!). From there, we took a closer look at the innovation behind our platforms, hearing directly from our senior staff and the scientists behind the technologies.
Missed the live event? Check out these 5 reasons to watch it on-demand:
1. Discover the technology behind our AVITI™ family of systems and see how it set the stage for continuous innovation.
Our co-founders shared how we reimagined every element of a sequencing platform to deliver a solution designed to evolve with the researchers’ needs. From decreased run times to higher output to flexible read lengths to Q50+ quality—we’ve been able to integrate these solutions onto a single benchtop platform. Plus, they’ll describe how this set the stage for continuous innovation with simplified workflows, onboard library prep, multiomic cytoprofiling, and scalability.
2. Learn how Trinity is revolutionizing hybrid selection technologies with onboard library prep.
The team behind Trinity shared how we’ve modernized the targeted sequencing workflow by eliminating or moving all steps post-hybridization onto the AVITI platform. You simply load the post-hybridization material onto the sequencing flow cell and the AVITI takes care of the rest without any changes to the run time. With 1-hour fast hybridization options, you can generate next-day results with improved library complexity compared to traditional workflows.
3. Take a deep dive into the science behind the AVITI24.
We know that sequencing itself doesn’t provide all the insights into the complexity of biology. You typically have to perform several experiments to really understand RNA expression, protein expression and phosphorylation events, and show morphology changes in your cells. Our team describes how we combined these different aspects of biology in the AVITI24—the first platform that enables both NGS and in situ multiomics.
We share the workflow, describe how we benchmarked our data, and demonstrate how we sensitively detected a heterogenous drug response across cell populations by combining multiomic readouts. With just one hour of hands-on time, we studied over 1 million cells to gain new insights into the biology of drug response.
4. Hear from early access customers about their experience using these technologies.
You’ll hear why some of our existing customers chose an AVITI—from flexibility and compatibility with existing workflows to quality and performance to cost—the AVITI met and continues to exceed their expectations.
“They’re willing to take the leap into different advancements. That’s something that you only get from new key players that are not only changing the field, but they’re actually listening to what researchers what.”
-Hannah Dose, Co-founder & CEO, AU Genomics
Early access Trinity users shared how it transformed their current workflows. Chris Frazar, PhD, Norwest Genomics Center at the University of Washington, noted that their standard protocols for exome sequencing include an overnight hybridization followed by several rounds of stringency washing, but with the one-hour fast hybridization option of the Trinity workflow, they saved nearly a day and a half through the process.
Plus, you’ll see why William Lai, PhD, Assistant Research Professor, Cornell University, is excited about the unlimited potential of the AVITI24. Dr. Lai gave us a first look into his teams’ AVITI24 data examining DNA damage response across different cancer cell types. In a single experiment, the AVITI24 provided data regarding cell cycle status and detected proteins and transcripts that were not only common to all cell types, but also those unique to a specific cell type. As Dr. Lai noted, “it has the potential to be enormously transformative in terms of actually viewing and understanding everything that we’re doing.”
5. Get a sneak peek into the future of these technologies
The innovation doesn’t stop here. We also share what’s next for Element in 2025 — including direct in situ sequencing on the AVITI24. Our ABC chemistry enables us to move beyond counting RNA transcripts and unlock direct sequencing in cells. We share preliminary data of this technology including targeted sequencing of specific genes and an unbiased view of the transcriptome by sequencing the 3’ untranslated region. Importantly, we can combine direct sequencing with cell paint and protein detection for a rich multiomic view of cell biology.
Get all these insights, plus additional resources and infographics to learn more about ABC sequencing, the Trinity workflow, and the unlimited potential of the AVITI24 at our Beyond content hub.